Type 2 Diabetes, Hepatic Steatosis
Conditions
Brief summary
The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and hepatic steatosis (fatty liver).
Interventions
OTHERMagnetic Resonance Liver Assessment
Liver fat will be measured by MR imaging to assess level of hepatic steatosis.
OTHERBike Exercise VO2max
Maximal fitness measured by cycle ergometer.
OTHERDEXA
Measure body composition (fat and lean body mass).
Sponsors
AdventHealth Translational Research Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Intervention model description
This research design is a cross-sectional, parallel trial with two groups: lean, healthy controls and individuals with T2D and hepatic steatosis.
Eligibility
Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
for individuals with T2D and elevated liver fat ≥5.6% 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or (pre-menopausal) female, aged 25-55 years 4. Body mass index (BMI) between 25 and 45 kg/m2 5. Sedentary (1 day or less per week of structured exercise) 6. Type 2 diabetes mellitus: HbA1c ≥7.5% 7. Liver fat ≥5.6% based on MRI 8. Weight stable (± 2 kg) for prior 3 months Inclusion criteria for lean, healthy controls 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or (pre-menopausal) female, aged 25-55 years 4. Body mass index (BMI) between 18.5 and 27.5 kg/m2 5. Normal liver fat (FibroScan CAP \<249dB/m, \<5.6% liver fat based on MRI) 6. Weight stable (± 2 kg) for prior 3 months 7. Active (≥3 day/week of structured exercise)
Exclusion criteria
1.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of Endogenous Glucose Production (EGP) | Day 14 | Bulk EGP will be measured during resting and exercise conditions to determine how Endogenous Glucose Production (EGP) differs during exercise (compared to no exercise) in T2D and Metabolic dysfunction associated steatotic liver disease (MASLD). |
Countries
United States
Contacts
Primary ContactRecruitment Department
Outcome results
None listed